Background and Purpose: This study summarizes the cranial stereotactic radio-
| INTRODUCTION
Volumetric modulated arc therapy (VMAT) has significantly changed the options for LINAC based cranial stereotactic radiosurgery (SRS) treatment of multiple metastatic brain lesions. Traditionally, LINAC based SRS utilizes one isocenter for each lesion, resulting in long treatment delivery times for patients with multiple metastases.
Recent publications have reported on VMAT planning for cranial SRS patients with multiple lesions using one isocenter and demonstrated that highly conformal dose distributions can be achieved.
1,2 Plan parameters have been compared to Gamma Knife plans which are considered the standard for cranial SRS treatment. 3, 4 These studies have shown that VMAT plans can produce target coverage and dose fall-off in the high dose area similar to Gamma Knife plans.
There are still challenges related to the dose accuracy of VMAT delivery for small targets and the accuracy of the VMAT dose calculation algorithm must be validated prior to releasing SRS VMAT. 5 In addition, setup accuracy becomes much more critical when multiple targets at a distance from the isocenter are treated in the same plan. 6 At our institution, we have developed a SRS VMAT planning technique for treatment of multiple cranial metastases using similar contouring and optimization technique to those published by Clark et al. 2 at the University of Alabama. Due to limitations in our calculation algorithm to model both the 2.5 and 5 mm leaves on the TrueBeam STx we limit the plans to use only the 2.5 mm leaves, often resulting in two isocenters for cases with multiple brain metastasis. In this study, we present plan quality parameters and treatment times for 40 patients, treating a total of 188 lesions, with single fraction doses ranging from 16-21 Gy. The planning procedures, plan criteria, and quality assurance methods implemented at our institution are presented. At our institution, the target dose inhomogeneity criteria for these iPlan cases were 125%. Target inhomogeneity was allowed to increase to 140% for the Eclipse SRS VMAT plans to reduce the dose to normal brain. For cases where the PTV overlapped with the brainstem, based on internal experience a dose-volume limit to brainstem of V 18 Gy ≤ 10% was used to allow for full coverage of the target. and T1-weighted (3 mm) magnetic resonance images were fused to the CT images using MIM (version 6.6.3; MIM Software Inc., Cleveland, OH, USA) and auto-segmentation of normal structures was also generated in this systems.
| MATERIALS AND METHODS

2.A | Preclinical dosimetry
2.B.2 | Treatment planning
The gross tumor volume (GTV) was contoured by the treating radiation oncologist who also reviewed and edited the critical structures (eyes, lenses, optic nerves, chiasm, brainstem, cord, and cochleas). A planning target volume (PTV) was created by a 3-dimensional 0-2 mm expansion around the GTV to account for imaging fusion
uncertainty, contouring variations, setup errors, and possible patient motion during treatment. The wall extraction tool in Eclipse was used to create similar shell structures for optimization as published by Clark et al. 2 The dimension of the shells depends on the PTV size. Separate shell structures were created for each group of targets with the same prescription dose. The planner also created a structure to evaluate the GI for each PTV.
Depending on the spatial distribution of the lesions one, two, or occasionally three isocenters were used. The planner created a union PTV for each group of lesions that were to be treated with the same isocenter and then placed the isocenter at the geometric center of the selected group of PTVs. The isocenter was then adjusted to ensure that Y1 and Y2 jaws were ≤4 cm so that only the 2. The prescribed dose to each lesion was based on lesion size and proximity to critical structures and other lesions. The initial dose volume constraints and priorities for planning follow the technique described by Clark et al. 2 The PTV for each target was used in the optimization and the dose constrain for each PTV adjusted during the optimization so PTV D 98% for all lesions with the same prescription are as similar as possible. The plan is normalized such that all PTVs meet the coverage criteria in Table 1 . The plan was normalized by setting 100% dose to cover at least 98% of the PTV volumes.
Additional dose constraints were added for critical structures when needed. CI and target dose HI were used for plan evaluation:
2.B.3 | Patient specific quality assurance
Patient-specific dosimetry was performed prior to treatment by scheduling and delivering the plan on an EPID. The EPID was validated to film measurements using the five preclinical plans where EPID and film measured gamma, c, (threshold 3%/2 mm) were in agreement within 3%. Measured dose was compared to the pre- 
3.A | Comparison of preclinical plans
Our VMAT planning procedures were developed to produce plans comparable to our clinical standard by analyzing five clinical cases T A B L E 1 Institutional plan criteria, where D max = maximum dose, D min = minimum dose, Rx = prescription dose, and V xGy = volume receiving x Gy.
Guideline Limit
Target criteria Table 3 . The dose to critical structures naturally depends on the proximity to the target lesions. Higher doses were accepted for cases where the lesions were close to the critical structures and these situations are apparent in Table 3 . For example, one patient had a PTV overlapping with brainstem resulting in a brainstem D max of 24.9 Gy. For this scenario, PTV coverage was prioritized as long as brainstem V 18 Gy ≤ 10%. In another patient, an optic nerve D max of 11.0 Gy was accepted due to the PTV proximity to the nerve. If any dose criteria were exceeded, a peer review process was initiated.
The target indexes GI, HI, and CI were collected for each PTV.
The CI is typically in the range 1.0-1.2. The maximum value of 2.9 occurred for a 0.05 cm 3 lesion in a 6-lesion plan. The median GI is 4.4. Figure 1 shows the GI for each lesion plotted versus PTV volume. Out of the 188 lesions, 13 lesions were so close that the 50% isodose was not split between the two lesions. These lesions were excluded from this GI analysis. For PTV sizes >0.5 cm 3 , a GI <5 is typically achievable whereas for smaller targets, GI exceeds 5.
The GI is reduced with increasing PTV size. Allowing the HI to increase facilitates a slight reduction in the GI for lesions ≥0.8 cm 3 as seen in Fig. 2 . This trend was not observed for the smaller lesions.
Isodose distributions for a typical plan with eight lesions and two isocenters are shown in Fig. 3(a) Figure 3(b) shows the arcs used for this case.
Two isocenters were used with five arcs at couch 0, 0, 40, 90, and 330 for each isocenter. The collimator for each arc was manually selected to minimizing situations in which there were two targets in the same leaf track.
The percent brain volume receiving 7 Gy or less is plotted in Fig. 4 as a function of the total tumor volume (sum of all PTVs) in each treatment plan. The plan goal is to keep brain V 7 Gy < 5% which is a criteria based on internal experience. For cases with a large tumor burden this criteria was not achieved.
Total beam-on time for each patient and beam-on time per
isocenter is listed in Table 4 To determine the percentage of patients that moved and were repositioned during treatment off-line review sessions for 240 single fraction cranial patients were reviewed. We found that 10 patients (4.2%) were repositioned during treatment. One patient was repositioned three times. Eight patients moved <1.1 mm (root-meansquare of shifts in all three translation directions), one patient moved 1.8 mm, and one patient moved 6.8 mm. The largest rotational changes were in the pitch angle with up to 1.5°, up to 1.4°in roll, and up to 0.6°in rotation.
| DISCUSSION
Several studies have compared the dose distribution and dosimetric parameters for Gamma Knife plans to VMAT plans for cases with multiple metastases. One study reported that VMAT plans provide superior conformity with no significant difference in dose fall off compared to Gamma Knife plans, 4 whereas another study found that VMAT plans had comparable conformity to Gamma Knife but that Gamma Knife remained superior in terms of dose fall off around the target. 9 Liu et al. found that VMAT plans provide better conformity but a larger GI than Gamma Knife, that moderate to low dose (3-6 Gy) isodose volumes were equivalent to Gamma Knife, and that Gamma Knife achieved smaller low-dose (<3 Gy) volumes. 3 The differences in GI will depend on the VMAT planning technique as well as on the size of the lesions, so a direct comparison between studies at different institutions is not necessarily possible. Our results comparing the VMAT plans to the delivered 3D plans using 10-12 static show that the GI is reduced with increasing target size so it is therefore expected that our reported GI is higher than in Clarks study where the lesion sizes were larger.
Ma et al. published a planning study comparing plans for Gamma
Knife, Cyber Knife, Novalis, and TrueBeam FFF for cases with 3, 6, 9, and 12 lesions, concluding that the volumes of brain receiving low to moderate dose (4-12 Gy) were higher and increased more rapidly with additional targets for LINAC-based SRS than for Gamma Knife. 10 In this study, all lesions were smaller than 1 cm 3 , whereas in our study the targets ranged from 0.05-17.74 cm 3 . Therefore, the brain volume receiving 12 Gy is higher in our study (range 4-57 cm From the preclinical VMAT planning we found that when increasing the HI while keeping the CI the same, the GI was reduced (data not shown). Other groups have reported reduction in GI with increasing HI. 11, 12 GI as a function of the dose HI for all PTVs ≥0.8 cm 3 is shown in Fig. 2 . There is no strong correlation between GI and HI from these clinical plans but there may have been different considerations or challenges in the plans that impacted the final HI and GI for each lesion. We decided to allow for a PTV D max of 140%. This is higher than for the iPlan plans that have been our clinical standard prior to introducing the VMAT technique but since Gamma Knife plans typically use a PTV D max >140% we accepted this higher inhomogeneity to reduce the GI. The risk of radiation The plan goal is to achieve brain V 7 Gy < 5%. | 181 treatment time is significantly reduced by using VMAT with one or two isocenters. Planning time for one or two lesion cases are significantly shorter for a 3D plan in iPlan than for VMAT in Eclipse.
Inverse planning requires contouring of optimization structures and running at least one optimization. Contouring time can be reduced by utilizing automatic segmentation of critical structures. We are using atlas auto-segmentation in MIM and a specifically designed workflow to create optimization structures for each VMAT case.
Isocenter position and arcs are placed once the CT and structure set is transferred to Eclipse. Due to limitations in the dose modeling we limit our plans to the 2. with lack of accurate dose modeling, software tools can be developed to assist with optimal grouping of targets into separate isocenters and plans that use only the 2.5 mm MLC leaves. 19 Similarly to what we found for the AAA dose calculation model Gardner et al.
reports the need to adjust source size for small field intracranial SRS using AcurosXB in the Eclipse planning system to avoid >10% central axis dose discrepancies for small target volumes. 20 When treating multiple targets distant from the isocenter, extra requirements are needed for setup accuracy and limitation of patient motion during treatment. To remove any patient rotation at setup, a 6DOF couch should be used for treatment. The positioning accuracy is determined by the CBCT-MV isocenter congruence, the amount of couch walk and the accuracy of the image registration at the machine. Motion monitoring with conventional LINAC on-board imaging is challenging due to limitations imposed by the routine use of couch rotations and gantry rotation for these patients. Using the optical surface image system AlignRT we found that few patients move during treatment in our frameless immobilization system. Most of the patients that moved (eight out of ten) had moved <1.1 mm but there were a couple of patients that moved significantly and this highlights the importance of using a motion monitoring system to catch these outliers. An alternative motion monitoring system frequently used for cranial SRS is ExacTrac (Brainlab, Munich, Germany).
| CONCLUSION
We have developed a procedure to treat multiple cranial metastases with VMAT achieving similar plan quality to traditional 3D LINAC based SRS plans. Caution must be taken to assure that the dose calculation model is accurate for very small lesions and for both MLC types on a TrueBeam STx. For cases with three or more lesions treatment time is significantly reduced by using VMAT plans and one or two isocenters. Currently it is very elaborate to create these treatment plans due to limitations in the dose modeling, and also due to contouring and optimization. Better dose modeling in Eclipse would remove limitations on the Y-jaw and thereby reduce planning and treatment time significantly.
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